Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B

By sjmartinez • April 2, 2024

Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. Antimicrob Agents Chemother. 2024 Apr 1:e0154523. doi: 10.1128/aac.01545-23. Epub ahead of print. PMID: 38557112.

Tags: combination therapy, Harbor UCLA, Ibrexafungerp, infection model, Infectious Diseases, liposomal amphotericin B, mouse, mucor, mucormycosis, posaconazole, Publications, Rhizopus

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Hypokalemic periodic paralysis presenting as cardiac arrest

Joshi M, Salameh W, Vintch J, Goodman EL. Hypokalemic periodic paralysis presenting as cardiac arrest. BMJ Case Rep. 2024 Nov 13;17(11):e259889. doi: 10.1136/bcr-2024-259889. PMID: 39537393.

Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort

Chien C, Cruz E Silva V, Geiter E, Meier D, Zimmermann H, Bichuetti DB, Idagawa MI, Altintas A, Tanriverdi U, Siritho S, Pandit L, Dcunha[...]